Header

UZH-Logo

Maintenance Infos

Browse by Creators

Navigate back| Up a level
Export as
Number of items: 31.

Dummer, Reinhard; Ascierto, Paolo A; Gogas, Helen J; Arance, Ana; Mandala, Mario; Liszkay, Gabriella; Garbe, Claus; Schadendorf, Dirk; Krajsova, Ivana; Gutzmer, Ralf; Chiarion-Sileni, Vanna; Dutriaux, Caroline; de Groot, Jan Willem B; Yamazaki, Naoya; Loquai, Carmen; Moutouh-de Parseval, Laure A; Pickard, Michael D; Sandor, Victor; Robert, Caroline; Flaherty, Keith T (2018). Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncology, 19(5):603-615.

Grob, Jean Jacques; Schadendorf, Dirk; Lorigan, Paul; Ascierto, Paolo; Larkin, James; Nathan, Paul; Robert, Caroline; Hauschild, Axel; Weber, Jeffrey; Daud, Adil; Hamid, Omid; Dummer, Reinhard; Hansson, Johan; Hoeller, Christoph; Schachter, Jacob; Van Akkooi, Alexander C J; Garbe, Claus (2018). Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. European Journal of Cancer, 91:168-170.

Kirchberger, Michael Constantin; Ugurel, Selma; Mangana, Johanna; Heppt, Markus Valentin; Eigentler, Thomas Kurt; Berking, Carola; Schadendorf, Dirk; Schuler, Gerold; Dummer, Reinhard; Heinzerling, Lucie (2018). MEK inhibition may increase survival of NRAS-mutated melanoma patients treated with checkpoint blockade: Results of a retrospective multicentre analysis of 364 patients. European Journal of Cancer, 98:10-16.

Long, Georgina V; Hauschild, Axel; Santinami, Mario; Atkinson, Victoria; Mandalà, Mario; Chiarion-Sileni, Vanna; Larkin, James; Nyakas, Marta; Dutriaux, Caroline; Haydon, Andrew; Robert, Caroline; Mortier, Laurent; Schachter, Jacob; Schadendorf, Dirk; Lesimple, Thierry; Plummer, Ruth; Ji, Ran; Zhang, Pingkuan; Mookerjee, Bijoyesh; Legos, Jeff; Kefford, Richard; Dummer, Reinhard; Kirkwood, John M (2017). Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma. New England Journal of Medicine, 377(19):1813-1823.

Hamid, Omid; Puzanov, Igor; Dummer, Reinhard; Schachter, Jacob; Daud, Adil; Schadendorf, Dirk; Blank, Christian; Cranmer, Lee D; Robert, Caroline; Pavlick, Anna C; Gonzalez, Rene; Hodi, F Stephen; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Gangadhar, Tara C; Wei, Ziwen; Ebbinghaus, Scot; Ibrahim, Nageatte; Ribas, Antoni (2017). Final analysis of a randomised trial comparing pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory advanced melanoma. European Journal of Cancer, 86:37-45.

Wolchok, Jedd D; Chiarion-Sileni, Vanna; Gonzalez, Rene; Rutkowski, Piotr; Grob, Jean-Jacques; Cowey, C Lance; Lao, Christopher D; Wagstaff, John; Schadendorf, Dirk; Ferrucci, Pier F; Smylie, Michael; Dummer, Reinhard; Hill, Andrew; Hogg, David; Haanen, John; Carlino, Matteo S; et al (2017). Overall survival with combined nivolumab and ipilimumab in advanced melanoma. New England Journal of Medicine, 377(14):1345-1356.

Schadendorf, Dirk; et al; Dummer, Reinhard (2017). Health-related quality of life results from the phase III CheckMate 067 study. European Journal of Cancer, 82:80-91.

Dummer, Reinhard; Schadendorf, Dirk; Ascierto, Paolo A; Arance, Ana; Dutriaux, Caroline; Di Giacomo, Anna Maria; Rutkowski, Piotr; Del Vecchio, Michele; Gutzmer, Ralf; Mandala, Mario; Thomas, Luc; Demidov, Lev; Garbe, Claus; Hogg, David; Liszkay, Gabriella; Queirolo, Paola; Wasserman, Ernesto; Ford, James; Weill, Marine; Sirulnik, L Andres; Jehl, Valentine; Bozón, Viviana; Long, Georgina V; Flaherty, Keith (2017). Binimetinib versus dacarbazine in patients with advanced NRAS -mutant melanoma (NEMO): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncology, 18(4):435-445.

Zimmer, Lisa; Apuri, Susmitha; Eroglu, Zeynep; Kottschade, Lisa A; Forschner, Andrea; Gutzmer, Ralf; Schlaak, Max; Heinzerling, Lucie; Krackhardt, Angela M; Loquai, Carmen; Markovic, Svetomir N; Joseph, Richard W; Markey, Kelly; Utikal, Jochen S; Weishaupt, Carsten; Goldinger, Simone M; Sondak, Vernon K; Zager, Jonathan S; Schadendorf, Dirk; Khushalani, Nikhil I (2017). Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma. European Journal of Cancer, 75:47-55.

Long, Georgina V; Weber, Jeffrey S; Larkin, James; Atkinson, Victoria; Grob, Jean-Jacques; Schadendorf, Dirk; Dummer, Reinhard; Robert, Caroline; Márquez-Rodas, Ivan; McNeil, Catriona; Schmidt, Henrik; Briscoe, Karen; Baurain, Jean-François; Hodi, F Stephen; Wolchok, Jedd D (2017). Nivolumab for Patients With Advanced Melanoma Treated Beyond Progression: Analysis of 2 Phase 3 Clinical Trials. JAMA Oncology, 3(11):1511.

Schadendorf, Dirk; Dummer, Reinhard; Hauschild, Axel; Robert, Caroline; Hamid, Omid; Daud, Adil; van den Eertwegh, Alfons; Cranmer, Lee; O'Day, Steven; Puzanov, Igor; Schachter, Jacob; Blank, Christian; Salama, April; Loquai, Carmen; Mehnert, Janice M; Hille, Darcy; Ebbinghaus, Scot; Kang, S Peter; Zhou, Wei; Ribas, Antoni (2016). Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma. European Journal of Cancer, 67:46-54.

Zimmer, Lisa; Goldinger, Simone M; Hofmann, Lars; Loquai, Carmen; Ugurel, Selma; Thomas, Ioannis; Schmidgen, Maria I; Gutzmer, Ralf; Utikal, Jochen S; Göppner, Daniela; Hassel, Jessica C; Meier, Friedegund; Tietze, Julia K; Forschner, Andrea; Weishaupt, Carsten; Leverkus, Martin; Wahl, Renate; Dietrich, Ursula; Garbe, Claus; Kirchberger, Michael C; Eigentler, Thomas; Berking, Carola; Gesierich, Anja; Krackhardt, Angela M; Schadendorf, Dirk; Schuler, Gerold; Dummer, Reinhard; Heinzerling, Lucie M (2016). Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy. European Journal of Cancer, 60:210-225.

Grob, Jean Jacques; Amonkar, Mayur M; Karaszewska, Boguslawa; Schachter, Jacob; Dummer, Reinhard; Mackiewicz, Andrzej; Stroyakovskiy, Daniil; Drucis, Kamil; Grange, Florent; Chiarion-Sileni, Vanna; Rutkowski, Piotr; Lichinitser, Mikhail; Levchenko, Evgeny; Wolter, Pascal; Hauschild, Axel; Long, Georgina V; Nathan, Paul; Ribas, Antoni; Flaherty, Keith; Sun, Peng; Legos, Jeffrey J; McDowell, Diane Opatt; Mookerjee, Bijoyesh; Schadendorf, Dirk; Robert, Caroline (2015). Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncology, 16(13):1389-1398.

Dummer, Reinhard; Schadendorf, Dirk; Ascierto, Paolo A; Larkin, James; Lebbé, Celeste; Hauschild, Axel (2015). Integrating first-line treatment options into clinical practice: what's new in advanced melanoma? Melanoma research, 25(6):461-469.

Van Allen, Eliezer M; Miao, Diana; Schilling, Bastian; Shukla, Sachet A; Blank, Christian; Zimmer, Lisa; Sucker, Antje; Hillen, Uwe; Geukes Foppen, Marnix H; Goldinger, Simone M; Utikal, Jochen; Hassel, Jessica C; Weide, Benjamin; Kaehler, Katharina C; Loquai, Carmen; Mohr, Peter; Gutzmer, Ralf; Dummer, Reinhard; Gabriel, Stacey; Wu, Catherine J; Schadendorf, Dirk; Garraway, Levi A (2015). Genomic correlates of response to CTLA4 blockade in metastatic melanoma. Science, 350(6257):207-211.

Ribas, Antoni; Puzanov, Igor; Dummer, Reinhard; Schadendorf, Dirk; Hamid, Omid; Robert, Caroline; Hodi, F Stephen; Schachter, Jacob; Pavlick, Anna C; Lewis, Karl D; Cranmer, Lee D; Blank, Christian U; O'Day, Steven J; Ascierto, Paolo A; Salama, April K S; Margolin, Kim A; Loquai, Carmen; Eigentler, Thomas K; Gangadhar, Tara C; Carlino, Matteo S; Agarwala, Sanjiv S; Moschos, Stergios J; Sosman, Jeffrey A; Goldinger, Simone M; Shapira-Frommer, Ronnie; Gonzalez, Rene; Kirkwood, John M; Wolchok, Jedd D; Eggermont, Alexander; Li, Xiaoyun Nicole; Zhou, Wei; Zernhelt, Adriane M; Lis, Joy; Ebbinghaus, Scot; Kang, S Peter; Daud, Adil (2015). Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology, 16(8):908-918.

Larkin, James; Chiarion-Sileni, Vanna; Gonzalez, Rene; Grob, Jean Jacques; Cowey, C Lance; Lao, Christopher D; Schadendorf, Dirk; Dummer, Reinhard; Smylie, Michael; Rutkowski, Piotr; Ferrucci, Pier F; Hill, Andrew; Wagstaff, John; Carlino, Matteo S; Haanen, John B; Maio, Michele; Marquez-Rodas, Ivan; McArthur, Grant A; Ascierto, Paolo A; Long, Georgina V; Callahan, Margaret K; Postow, Michael A; Grossmann, Kenneth; Sznol, Mario; Dreno, Brigitte; Bastholt, Lars; Yang, Arvin; Rollin, Linda M; Horak, Christine; Hodi, F Stephen; Wolchok, Jedd D (2015). Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. New England Journal of Medicine, 373(1):23-34.

Robert, Caroline; Karaszewska, Boguslawa; Schachter, Jacob; Rutkowski, Piotr; Mackiewicz, Andrzej; Stroiakovski, Daniil; Lichinitser, Michael; Dummer, Reinhard; Grange, Florent; Mortier, Laurent; Chiarion-Sileni, Vanna; Drucis, Kamil; Krajsova, Ivana; Hauschild, Axel; Lorigan, Paul; Wolter, Pascal; Long, Georgina V; Flaherty, Keith; Nathan, Paul; Ribas, Antoni; Martin, Anne-Marie; Sun, Peng; Crist, Wendy; Legos, Jeff; Rubin, Stephen D; Little, Shonda M; Schadendorf, Dirk (2015). Improved overall survival in melanoma with combined dabrafenib and trametinib. New England Journal of Medicine, 372(1):30-39.

Lorigan, Paul; Ascierto, Paolo A; Dummer, Reinhard; Eggermont, Alexander M; Flaherty, Keith T; Garbe, Claus; Gogas, Helen; Hauschild, Axel; Kefford, Richard F; Kirkwood, John M; Larkin, James; Long, Georgina V; Maio, Michele; McArthur, Grant A; Ribas, Antoni; Robert, Caroline; Schadendorf, Dirk; Sondak, Vernon K; Wolchok, Jedd D; Hudson, Andrew M (2015). Expanded access programmes: patient interests versus clinical trial integrity. Lancet Oncology, 16(1):15-17.

Espinosa, Enrique; Grob, Jean-Jacques; Dummer, Reinhard; Rutkowski, Piotr; Robert, Caroline; Gogas, Helen; Kefford, Richard; Eggermont, Alexander M M; Martin Algarra, Salvador; Hauschild, Axel; Schadendorf, Dirk (2015). Treatment Algorithms in Stage IV Melanoma. American Journal of Therapeutics, 22(1):61-67.

McCusker, Margaret; Basset-Seguin, Nicole; Dummer, Reinhard; Lewis, Karl; Schadendorf, Dirk; Sekulic, Aleksandar; Hou, Jeannie; Wang, Lisa; Yue, Huibin; Hauschild, Axel (2014). Metastatic basal cell carcinoma: Prognosis dependent on anatomic site and spread of disease. European Journal of Cancer, 50(4):774-783.

McArthur, Grant A; Chapman, Paul B; Robert, Caroline; Larkin, James; Haanen, John B; Dummer, Reinhard; Ribas, Antoni; Hogg, David; Hamid, Omid; Ascierto, Paolo A; Garbe, Claus; Testori, Alessandro; Maio, Michele; Lorigan, Paul; Lebbé, Celeste; Jouary, Thomas; Schadendorf, Dirk; O'Day, Stephen J; Kirkwood, John M; Eggermont, Alexander M; Dréno, Brigitte; Sosman, Jeffrey A; Flaherty, Keith T; Yin, Ming; Caro, Ivor; Cheng, Suzanne; Trunzer, Kerstin; Hauschild, Axel (2014). Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncology, 15(3):323-332.

Flaherty, Keith T; Hennig, Michael; Lee, Sandra J; Ascierto, Paolo A; Dummer, Reinhard; Eggermont, Alexander M M; Hauschild, Axel; Kefford, Richard; Kirkwood, John M; Long, Georgina V; Lorigan, Paul; Mackensen, Andreas; McArthur, Grant; O'Day, Steven; Patel, Poulam M; Robert, Caroline; Schadendorf, Dirk (2014). Surrogate endpoints for overall survival in metastatic melanoma: a meta-analysis of randomised controlled trials. Lancet Oncology, 15(3):297-304.

Van Allen, Eliezer M; Wagle, Nikhil; Sucker, Antje; Treacy, Daniel J; Johannessen, Cory M; Goetz, Eva M; Place, Chelsea S; Taylor-Weiner, Amaro; Whittaker, Steven; Kryukov, Gregory V; Hodis, Eran; Rosenberg, Mara; McKenna, Aaron; Cibulskis, Kristian; Farlow, Deborah; Zimmer, Lisa; Hillen, Uwe; Gutzmer, Ralf; Goldinger, Simone M; Ugurel, Selma; Gogas, Helen J; Egberts, Friederike; Berking, Carola; Trefzer, Uwe; Loquai, Carmen; Weide, Benjamin; Hassel, Jessica C; Gabriel, Stacey B; Carter, Scott L; Getz, Gad; Garraway, Levi A; Schadendorf, Dirk (2014). The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma. Cancer Discovery, 4(1):94-109.

Goldinger, Simone M; Zimmer, Lisa; Schulz, Carsten; Ugurel, Selma; Hoeller, Christoph; Kaehler, Katharina C; Schadendorf, Dirk; Hassel, Jessica C; Becker, Juergen; Hauschild, Axel; Dummer, Reinhard (2014). Upstream mitogen-activated protein kinase (MAPK) pathway inhibition: MEK inhibitor followed by a BRAF inhibitor in advanced melanoma patients. European Journal of Cancer, 50(2):406-410.

Ascierto, Paolo A; Schadendorf, Dirk; Berking, Carola; Agarwala, Sanjiv S; van Herpen, Carla Ml; Queirolo, Paola; Blank, Christian U; Hauschild, Axel; Beck, J Thaddeus; St-Pierre, Annie; Niazi, Faiz; Wandel, Simon; Peters, Malte; Zubel, Angela; Dummer, Reinhard (2013). MEK162 for patients with advanced melanoma harbouring NRAS or Val600 BRAF mutations: a non-randomised, open-label phase 2 study. Lancet Oncology, 14(3):249-256.

Robert, Caroline; Dummer, Reinhard; Gutzmer, Ralf; Lorigan, Paul; Kim, Kevin B; Nyakas, Marta; Arance, Ana; Liszkay, Gabriella; Schadendorf, Dirk; Cantarini, Mireille; Spencer, Stuart; Middleton, Mark R (2013). Selumetinib plus dacarbazine versus placebo plus dacarbazine as first-line treatment for BRAF-mutant metastatic melanoma: a phase 2 double-blind randomised study. Lancet Oncology, 14(8):733-740.

Niessner, Heike; Forschner, Andrea; Klumpp, Bernhard; Honegger, Jürgen B; Witte, Maria; Bornemann, Antje; Dummer, Reinhard; Adam, Annemarie; Bauer, Jürgen; Tabatabai, Ghazaleh; Flaherty, Keith; Sinnberg, Tobias; Beck, Daniela; Leiter, Ulrike; Mauch, Cornelia; Roesch, Alexander; Weide, Benjamin; Eigentler, Thomas; Schadendorf, Dirk; Garbe, Claus; Kulms, Dagmar; Quintanilla-Martinez, Leticia; Meier, Friedegund (2013). Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases. Cancer Medicine, 2(1):76-85.

Voskens, Caroline J; Goldinger, Simone M; Loquai, Carmen; Robert, Caroline; Kaehler, Katharina C; Berking, Carola; Bergmann, Tanja; Bockmeyer, Clemens L; Eigentler, Thomas; Fluck, Michael; Garbe, Claus; Gutzmer, Ralf; Grabbe, Stephan; Hauschild, Axel; Hein, Rüdiger; Hundorfean, Gheorghe; Justich, Armin; Keller, Ullrich; Klein, Christina; Mateus, Christine; Mohr, Peter; Paetzold, Sylvie; Satzger, Imke; Schadendorf, Dirk; Schlaeppi, Marc; Schuler, Gerold; Schuler-Thurner, Beatrice; Trefzer, Uwe; Ulrich, Jens; Vaubel, Julia; von Moos, Roger; Weder, Patrik; Wilhelm, Tabea; Göppner, Daniela; Dummer, Reinhard; Heinzerling, Lucie M (2013). The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS ONE, 8(1):e53745.

Zimmer, Lisa; Hillen, Uwe; Livingstone, Elisabeth; Lacouture, Mario E; Busam, Klaus; Carvajal, Richard D; Egberts, Friederike; Hauschild, Axel; Kashani-Sabet, Mohammed; Goldinger, Simone M; Dummer, Reinhard; Long, Georgina V; McArthur, Grant; Scherag, André; Sucker, Antje; Schadendorf, Dirk (2012). Atypical Melanocytic Proliferations and New Primary Melanomas in Patients With Advanced Melanoma Undergoing Selective BRAF Inhibition. Journal of Clinical Oncology, 30(19):2375-2383.

Eggermont, Alexander M M; Suciu, Stefan; Testori, Alessandro; Santinami, Mario; Kruit, Wim H J; Marsden, Jeremy; Punt, Cornelis J A; Salès, François; Dummer, Reinhard; Robert, Caroline; Schadendorf, Dirk; Patel, Poulam M; de Schaetzen, Gaetan; Spatz, Alan; Keilholz, Ulrich (2012). Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. Journal of Clinical Oncology, 30(31):3810-3818.

This list was generated on Fri Jun 22 00:16:26 2018 CEST.